The molecular classification could have meaningful implications both for FST management and prognostic value; for example, POLE-mutated carcinomas could respond better to conservative treatment; conversely, MSI/MMRd ECs are unlikely to respond to a similar approach or show a higher recurrence rate after initial regression, while in p53abn, an FST approach could be inappropriate [56,58,59]. This evidence concerns the gene POLE and carcinoma.